Meta-Analysis of Association between PALB2 Polymorphisms and Breast Cancer

Background: Previous studies have assessed associations between single nucleotide polymorphisms (SNPs) ofthe Partner and localizer of BRCA2 (PALB2) gene and risk of breast cancer. However, the results of these studiesare not consistent. Materials and Methods: We designed a meta-analysis to obtain a more reliable appraisal ofthe association between SNPs in the PALB2 gene and the susceptibility to breast cancer. We searched PubMed, Googlescholar and Embase databases and selected six studies with sufficient data to estimate the pooled odds ratios (ORs)and 95% confidence intervals (CIs). Results: Statistical analyses showed that the rs120963 was associated with breastcancer risk in allelic (OR (95% CI) = 1.33 (1.18-1.49)), homozygous (OR (95% CI) = 1.74 (1.31-2.32)), dominant(OR (95% CI) = 1.42 (1.22, 1.65)) and recessive (OR (95% CI) = 1.54 (1.17, 2.03)) models. The rs249954 andrs16940342 were associated with breast cancer risk in allelic (OR (95% CI) = 1.13 (1.04, 1.23) and 1.12 (1.01, 1.24)respectively) and dominant (OR (95% CI) = 1.23 (1.09, 1.39) and 1.18 (1.04, 1.33) respectively) models. The rs249935and rs447529 SNPs were associated with breast cancer in homozygous (OR (95% CI) = 0.67 (0.46, 0.97) and 0.51(0.30, 0.89) respectively) and recessive (OR (95% CI) = 0.65 (0.45, 0.95) and 0.51 (0.30, 0.88) respectively) models.Conclusions: The current meta-analysis shows the associations between five SNPs of PALB2 and breast cancer riskand confirms the results of previous studies regarding the role of this gene in the pathogenesis of breast cancer.     

Association between rs1862513 and rs3745367 Genetic Polymorphisms of Resistin and Risk of Cancer: A Meta-Analysis

The present study aimed to assess any associations between resistin gene (RETN) polymorphisms and cancersusceptibility by conducting a meta-analysis. A comprehensive literature search was performed with PubMed, Web ofScience, Scopus and Google Scholar for relevant studies published before April 2018. For the rs1862513 polymorphism,data from 9 studies covering 1,951 cancer patients and 2,295 healthy controls were included in this meta-analysis. Pooledodds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Our meta-analysis revealed that this RETNpolymorphism significantly increased the risk of cancer in codominant (OR=1.23, 95% CI= 1.01-1.50, p=0.04, CG vs CC;and OR=1.25, 95% CI= 1.03-1.53, p=0.03, GG vs CC), dominant (OR=1.19, 95% CI= 1.05-1.35, p=0.006, CG+GG vs CC),  CI= 1.00-1.30, p=0.04, G vs C) inheritance genetic models. Stratification analysis by cancertype revealed that the rs1862513 variant significantly increased the risk of colorectal and breast cancer, and that canceroverall in Caucasians (OR=1.22, 95% CI= 1.04-1.43, p=0.02, CG+GG vs CC; OR=1.18, 95% CI= 1.04-1.34, p=0.01,G vs C). The data revealed no correlation between the rs3745367 polymorphism and cancer risk. Further well-designedstudies with larger sample sizes and different ethnicities are warranted to validate the present findings.     

Association between IL-27 Gene Polymorphisms and Cancer Susceptibility in Asian Population: A Meta-Analysis

Background: Interleukin 27 (IL-27) has potent antitumor activity. Several epidemiological studies have designated that genetic variants of the IL-27 gene may contribute to various cancer susceptibility, but the data were inconclusive.  Objective: The current meta-analysis aimed to address the association between IL-27 rs153109, rs17855750, and rs181206 polymorphisms and the risk of cancer. Data Sources: Our team has selected eligible studies up to May 1, 2020, from several electronic databases, including Web of Science, PubMed, Scopus, and Google Scholar databases. Results: Our meta-analysis revealed that the carriers rs153109 A>G polymorphism in the IL-27 gene have higher risks of diseases in the heterozygous (OR=1.26, 95%CI=1.06-1.49, P=0.007, AG vs AA), homozygous (OR=1.18, 95%CI=1.01-1.37, p=0.33, GG vs AA), dominant (OR=1.25, 95%CI=1.07-1.47, P=0.006, AG+GG vs AA), and allele (OR=1.15, 95%CI=1.04-1.27, P=0.008, G vs A) genetic models. Stratified analysis by cancer type indicated that this variant was significantly associated with gastrointestinal cancer, colorectal cancer and breast cancer. The findings did not support an association between rs17855750 T>G, rs181206 T>C polymorphisms of IL-27 and cancer risk. Conclusion: the current study findings suggest that IL-27 rs153109 polymorphism significantly increased the risk of cancer susceptibility. Well-designed replication in a larger independent genetic association study with larger sample sizes in diverse ethnicities is required to verify the findings.     

Association of IL-10 rs1800871 and rs1800872 Polymorphisms with Breast Cancer Risk: A Systematic Review and Meta-Analysis

Background: The rs1800871 and rs1800872 polymorphisms of interleukin 10 (IL-10) gene has been indicated tobe associated with breast cancer (BC) risk, but study results are still debatable. To derive a more precise evaluation, weperformed a comprehensive meta-analysis. Methods: Multiple electronic databases were searched to identify studiesassessing the IL-10 rs1800871 and rs1800872 polymorphisms with BC risk. Results: A total of 21 case-control studieswith 6054 cases and 6355 controls were included in this met-analysis. There was a significant association between thers1800871 polymorphism and BC risk (CT vs. TT: OR= 1.17, 95% CI 1.01-1.35, p=0.02; and CC+CT vs. TT: OR= 1.29,95% CI 1.00-1.66, p=0.04). Moreover, increased BC risks were also associated with the rs1800872 polymorphism (Cvs. A: OR= 1.29, 95% CI 1.04-1.60, p=0.01; CC vs. AA: OR= 1.54, 95% CI 1.03-2.30, p=0.03; CC+CA vs. AA: OR=1.43, 95% CI 1.01-2.01, p=0.03; and CC vs. CA+AA: OR= 1.23, 95% CI 1.01-1.51, p=0.04). A pooling of the studieswas also conducted by ethnicity, but failed to show an association of IL-10 rs1800871 and rs1800872 polymorphismwith BC risk in Asians and Caucasians. Conclusions: Our results are inconsistent with previous meta-analysis suggeststhat IL-10 rs1800871 and rs1800872 polymorphisms might contribute to BC susceptibility in overall population, butnot by ethnicity.     

Association between Polymorphisms of ERCC5 Gene and Susceptibility to Gastric Cancer: A Systematic Review and Meta-Analysis

Background: several epidemiological studies have suggested that polymorphisms of the Excision Repair Cross Complementing Group-5 (ERCC5) gene might be related to gastric cancer risk; however, the results have been inconsistent or controversial. Therefore, we have performed a systematic review and meta-analysis to clarify the association between the ERCC5 gene polymorphisms and gastric cancer risk. Materials and Methods: An electronic search was conducted of several databases, including PubMed, Web of Science, and Google Scholar for articles that describe the association between polymorphisms of the ERCC5 gene and susceptibility of gastric cancer. Results: A total of 33 case control studies in 15 publications were included in the present meta-analysis. There were significant associations between gastric cancer susceptibility and ERCC5 gene rs751402 C>T (T vs. C: OR = 1.166, 95% C = 1.066-1.274, p= 0.001; TT vs. CC: OR = 0.723, 95% CI = 0.587-0.890, p = 0.002; TT+TC vs. CC: OR = 0.853, 95% CI = 0.757-0.961, p = 0.009; TT vs. TC+CC: OR = 0.793, 95% CI = 0.659-0.955, p = 0.015), rs2296147 T>C (C vs. T: OR = 1.268, 95% C = 1.049-1.532, p= 0.014), rs873601 G>A polymorphisms (A vs. G, OR = 1.087, 95% C = 1.021-1.159, p= 0.010; AA vs. GG, OR = 1.184, 95% CI = 1.043-1.343, p = 0.009, AA vs. AG+GG, OR = 1.156, 95% CI = 1.040-1.284, p = 0.007), but not rs2094258 C>T and rs1047768 T>C. Conclusion: the current meta-analysis demonstrates that rs751402 C>T, rs2296147 T>C, and rs873601 G>A polymorphisms of ERCC5 gene are associated with the susceptibility of gastric cancer.     

Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis

Background

Hereditary hemochromatosis (HH) is an autosomal recessive disorder mainly associated with homozygosity for the C282Y and H63D mutations in the hemochromatosis (HFE) gene. The reports about the C282Y and H63D mutations and hepatocellular carninoma (HCC) were controversial. To clarify the relationship between C282Y and H63D mutations and HCC, a meta-analysis including nine studies (1102 HCC cases and 3766 controls, mainly came from European populations) was performed.

Methods

The association was measured using random-effect (RE) or fixed-effect (FE) odds ratios (ORs) combined with 95% confidence intervals (CIs) according to the studies'' heterogeneity.

Results

Meta-analysis of nine studies showed that Y allele of C282Y was associated with HCC risk: RE OR reached 1.50 (95%CI: 1.05-2.14, p for heterogeneity = 0.02, I² = 0.57). Subgroup analysis of seven studies also showed Y allele was associated with HCC risk in healthy populations: RE OR reached 1.61 (95%CI: 1.08-2.39, p for heterogeneity = 0.04, I² = 0.55). We further did subgroup analysis in alcoholic liver cirrhosis (LC) patients of four studies (224 cases and 380 controls) and found that both the dominant model and Y allele of C282Y were associated with HCC risk (FE OR reached 4.06, 95%CI: 2.08-7.92 and 3.41, 95%CI: 1.81-6.41, respectively). There was no distinct heterogeneity among the studies (I² = 0). Sensitivity analyses showed the results were robust in the subgroup analysis of alcoholic LC patients.

Conclusions

C282Y mutation was associated with HCC in European alcoholic LC patients.     

Lack of any Association between Insertion/Deletion (I/D) Polymorphisms in the Angiotensin-converting Enzyme Gene and Digestive System Cancer Risk: a Meta-analysis

Objective: To investigate the association between the gene polymorphisms of angiotensin-converting enzyme(ACE) and digestive system cancer risk. Method: A search was performed in Pubmed, Medline, ISI Web ofScience and Chinese Biomedical (CBM) databases, covering all studies until Sep 1st, 2013. Statistical analysiswas performed by using Revman5.2 and STATA 12.0. Results: A total of 15 case-control studies comprising 2,390digestive system cancer patients and 9,706 controls were identified. No significant association was found betweenthe I/D polymorphism and digestive cancer risk (OR =0.93, 95%CI = (0.75, 1.16), P =0.53 for DD+DI vs. II). Inthe subgroup analysis by ethnicity and cancer type, no significant associations were found for the comparisonof DD+DI vs. II. Results from other comparative genetic models also indicated a lack of associations betweenthis polymorphism and digestive system cancer risks. Conclusions: This meta-analysis suggested that the ACED/I polymorphism might not contribute to the risk of digestive system cancer.     

Association between the TP53BP1 rs2602141 A/C Polymorphism and Cancer Risk: A Systematic Review and Meta-Analysis

Background: The p53-binding protein 1 (TP53BP1) gene may be involved in the development of cancer throughdisrupting DNA repair. However, investigation of associations between TP53BP1 rs2602141 A/C polymorphismand cancer have yielded contradictory and inconclusive outcomes. We therefore performed a meta-analysis toevaluate the association between the TP53BP1 rs2602141 A/C polymorphism and cancer susceptibility. Materialsand Methods: Published literature from PubMed, Medline, the Cochrane Library, EMbase, Web of Science,Google (scholar), CBMDisc, Chongqing VIP database, and CNKI database were retrieved. Pooled odds ratios(ORs) with 95% confidence intervals (CIs) were calculated using fixed or random-effects models. Publicationbias was estimated using funnel plots, Begg’s and Egger’s test. Results: A total of seven studies (3,018 casesand 5,548 controls) were included in the meta-analysis. Our results showed that the genotype distribution ofTP53BP1 rs2602141 A/C was not associated with cancer risk overall. However, on subgroup analysis, we foundthat TP53BP1 rs2602141 A/C was associated with cancer risk within an allele model (A vs C, OR=1.14, 95%CI:1.01-1.29) and a codominant model (AA vs CC, OR=1.36, 95%CI: 1.06-1.74) in Asians rather than in Caucasians.Subgroup analysis by cancer type, genotype, and with or without adjustment for controls showed no significantassociation. Conclusions: The findings suggested an association between rs2602141 A/C polymorphism in TP53BP1gene and increased risk of cancer in Asians.     

Association Between Three eNOS Polymorphisms and Cancer Risk: a Meta-analysis

Polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may influence the risk of cancer, but the results are still debatable. Therefore, we performed a systematic review to provide a more complete picture and conducted a meta-analysis to derive a precise estimation. We searched PubMed, EMBASE, EBSCO, Google Scholar and China National Knowledge Infrastructure (CNKI) databases until April 2014 to identify eligible studies. Thirty-one studies with cancer patients and controls were included in the meta-analysis. Overall, thepolled analysis revealed that the T-786C polymorphism was significantly associated with increased cancer risk under multiple genetic models (C vs T: OR=1.135, 95%CI=1.048-1.228; CC vs TT: OR=1.278, 95%CI=1.045-1.562; TC vsTT: OR=1.136, 95%CI=1.023-1.261; CC+TC vs TT: OR=1.159, 95%CI=1.047-1.281; CC vs TC+TT: OR=1.204, 95%CI= 1.003-1.447). G894T was associated with significant risk for females (TT vs GG: OR=1.414, 95%CI=1.056-1.892; TT vs GT+GG: OR=1.356, 95%CI=1.108-1.661) and for breast cancer (T vs G: OR=1.097, 95%CI=1.001-1.203; TT vs GG: OR=1.346, 95%CI=1.012-1.789; TT vs GT+GG: OR=1.269, 95%CI=1.028-1.566). Increased susceptibility was revealed for prostate cancer with 4a/b (ba vs bb: OR=1.338, 95%CI=1.013-1.768; aa+ba vs bb: OR=1.474, 95%CI=1.002-2.170). This meta-analysis indicated that the eNOS T-786C polymorphism is associated with elevated cancer risk; the G894T polymorphism contributes to susceptibility to breast cancer and cancer generally in females; and the 4a/b polymorphism may be associated with prostate cancer risk.     

Association of Promoter Region Polymorphisms of IL-10 Gene with Susceptibility to Lung Cancer: Systematic Review and Meta-Analysis

Objective: Epidemiological studies have suggested that the promoter region polymorphisms of interleukin-10 (IL-10)gene may be associated with an increased risk of lung cancer. However, those studies results are controversial. Thus, acomprehensive meta-analysis was performed to evaluate the association of promoter region polymorphisms of IL-10gene with susceptibility to lung cancer. Methods: a comprehensive search of PubMed, EMBASE, and CNKI databaseswas performed to find all eligible studies up to September 15, 2018. The pooled odds ratios (ORs) with 95% confidenceintervals (CIs) were used to assess the strength of such association. Results: A total number of 19 case-control studies with4084 cases and 6,131 controls were selected. The overall meta-analysis results showed that the -592A>C polymorphismwas significantly associated with lung cancer risk under four genetic models, i.e., allele (CT vs. TT: OR= 1.17, 95% CI1.01-1.35, p=0.02), homozygote (CC vs. AA: OR= 1.64, 95% CI 1.29-2.02, p≤0.001), heterozygote (CA vs. AA: OR=1.26, 95% CI 1.06-1.50, p≤0.001), and dominant (CC+CA vs. AA: OR= 1.31, 95% CI 1.11-1.54, p=0.001). However,there was no significant association between -819T>C and -1082A>G polymorphisms of IL-10 and lung cancer risk.Similarly, subgroup analyses by ethnicity detected significant association between IL-10 -592A>C and lung canceramong Asians and Caucasians. Conclusions: Our meta-analysis suggests that the IL-10 -592A>C polymorphism mightbe risk factor for lung cancer, especially among Asian and Caucasians. In contrast, the IL-10 -819T>C and -1082A>Gpolymorphisms are not significantly associated with increased risk of lung cancer.     

GSTM1 Polymorphisms and Lung Cancer Risk in the Chinese Population: a Meta-Analysis Based on 47 Studies

Although a number of studies have been conducted on the association between GSTM1 polymorphismsand lung cancer in China, this association remains elusive and controversial. To clarify the effects of GSTM1polymorphisms on the risk of lung cancer, a meta-analysis was performed in the Chinese population. Relatedstudies were identified from PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform,Chinese National Knowledge Infrastructure (CNKI), and Chinese Biology Medicine (CBM) up to 5th April 2014.A total of 45 articles (47 studies) including 6,623 cases and 7,865 controls were involved in this meta-analysis.Overall, a significant association (OR = 1.45, 95%CI: 1.32-1.60) was found between the null GSTM1 and lungcancer risk when all studies in Chinese population pooled into the meta-analysis. In subgroup analyses stratifiedby quality score, geographic area and source of controls, the same results were observed under all the models.This meta-analysis showed that the null GSTM1 may be a potential biomarker for lung cancer risk in Chinese,but further studies with gene-gene and gene-environment interactions are required for definite conclusions.     

Association between IL-18 -607 C/A Polymorphism and the Risk of Prostate Cancer: A Meta-Analysis of Case-Control Studies

Background: Accumulating evidence shows that cytokines play an important role in the proliferation of prostatecancer. This research is trying to determine that IL-18 -607 C/A polymorphism confers susceptibility to prostate cancer.Methods: Meta-analysis was used to collect data. The relevant studies were identified through a comprehensive searchfrom PubMed, Excerpta Medica Database (EMBASE), Web of Science, and Chinese Biomedical Literature Database(CBM) to obtain related studies published up to December 6, 2017. The association between interleukin (IL)-18 -607 C/Apolymorphism and prostate cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals(CIs). Results: Nine case-control studies from 6 articles were eventually identified. In the overall population, there is asignificant association between IL-18 -607 C/A polymorphism and prostate cancer risk in recessive (CC versus CA/AA:OR = 0.20, 95% CI = 0.15-0.27, P = 0.000) or dominant (CC/CA versus AA:OR = 0.42, 95% CI = 0.30–0.57, P = 0.000)models. In the sub-group analysis according to ethnicity, for Asians, IL-18 -607 C/A polymorphism was significantlyassociated with prostate cancer in allele contrast (C versus. A: OR=0.82, 95%CI=0.70-0.97, P=0.019), homozygote(CC versus. AA: OR=0.68, 95%CI=0.50-0.92, P=0.013), recessive (CC versus. CA/AA: OR=0.19, 95%CI=0.13-0.27,P=0.000), and dominant (CC/CA versus. AA: OR=0.37, 95%CI=0.28-0.48, P=0.000) models, for Caucasians, IL-18-607 C/A polymorphism was significantly associated with prostate cancer risk in allele contrast (C versus. A: OR=1.27,95%CI=1.02-1.58, P=0.033), homozygote (CC versus. AA: OR=1.86, 95%CI=1.19-2.91, P=0.007) and recessive (CCversus. CA/AA: OR=0.25, 95%CI=0.19-0.33, P=0.000) models. Conclusion: This meta-analysis has shown that IL-18-607 C/A polymorphism contributes to a decreased risk of prostate cancer risk in the Asian population but an increasedrisk in the Caucasian population.     

Genetic Association of XRCC1 Gene rs1799782, rs25487 and rs25489 Polymorphisms with Risk of Thyroid Cancer: a Systematic Review and Meta-Analysis

Background: A number of case-control studies have evaluated associations between the X-ray cross complementary group 1 protein (XRCC1) gene rs1799782 (Arg194Trp), rs25487 (Arg399Gln) and rs25489 (Arg280His) polymorphisms and thyroid cancer (TC) risk, but the results remain inconclusive. Materials and Methods: A systematic literature search was performed using PubMed and Google Scholar Search. According to defined criteria data were extracted and pooled odds ratios with 95% confidence intervals were calculated under five genetic models. Results: A total of 8 studies with 1,672 cases and 2,805 controls for the rs1799782 polymorphism, 14 studies with 2,506 cases and 5,180 controls for the rs25487 polymorphism, and 11 studies with 2,197 cases and 4,761 controls for the rs25489 polymorphism were included in this meta-analysis. Overall, there was a statistical association between XRCC1 rs1799782 polymorphism and TC risk with the homozygote genetic model (TT vs. CC: OR = 1.815, 95% CI = 1.115-2.953, p= 0.016) and the recessive genetic model (TT vs. TC+CC: OR = 1.854, 95% CI = 1.433-2.399, p= <0.001). In the subgroup analysis by ethnicity, significantly increased TC risk was observed only in Asians under the recessive model (TT vs. TC+CC: OR = 1.816, 95% CI = 1.398-2.358, p= <0.001). In addition, there was no positive association between XRCC1 rs25487 and rs25489 polymorphisms and risk of TC. However, there was a significant association between XRCC1 rs25487 polymorphism risk of TC among Caucasians with allele genetic comparison (A vs. G: OR= 0.882, 95% CI = 0.794-0.979, p= 0.136) and dominant genetic comparison (AA+AG vs. GG: OR=0.838, 95% CI = 0.728-0.965, p= 0.014). Conclusions: The results of our meta-analysis suggest an increased risk of TC with the XRCC1 rs1799782 and rs25487 polymorphisms. However, the XRCC1 rs25489 polymorphism appeared to be without influence.     

Significant Association of Alpha-Methylacyl-CoA Racemase Gene Polymorphisms with Susceptibility to Prostate Cancer: a Meta-Analysis

Background: Alpha-methylacyl-CoA racemase(AMACR) is thought to play key roles in diagnosis andprognosis of prostate cancer. However, studies of associations between AMACR gene polymorphisms andprostate cancer risk reported inconsistent results. Therefore, we conducted the present meta-analysis to clarifythe link between AMACR gene polymorphisms and prostate cancer risk. Materials and Methods: A literaturesearch was performed in PubMed, Embase, China National Knowledge Infrastructure (CNKI), Wanfang andWeipu databases. Odds ratios (ORs) and 95% confidence intervals (95%CIs) were calculated to assess thestrength of any association between AMACR polymorphisms and prostate cancer risk. Subgroup analyses byethnicity, source of controls, quality control and sample size were also conducted. Results: Five studies covering3,313 cases and 3,676 controls on five polymorphisms (D175G, M9V, S201L, K277E and Q239H) were includedin this meta-analysis. Significant associations were detected between prostate cancer and D175G (dominantmodel: OR=0.89, 95%CI=0.80-0.99, P=0.04) and M9V (dominant model: OR=0.87, 95%CI=0.78-0.97, P=0.01)polymorphisms as well as that in subgroup analyses. We also observed significant decreased prostate cancer riskin the dominant model (OR=0.90, 95%CI=0.81-0.99, P=0.04) for the S201L polymorphism. However, K277Eand Q239H polymorphisms did not appear to be related to prostate cancer risk. Conclusions: The current metaanalysisindicated that D175G and M9V polymorphisms of the AMACR gene are related to prostate cancer. TheS201L polymorphism might also be linked with prostate cancer risk to some extent. However, no associationwas observed between K277E or Q239H polymorphisms and susceptibility to prostate cancer.     

Association of Functional Polymorphisms of the XRCC4 Gene with the Risk of Breast Cancer: A Meta-analysis

Objective: X-ray cross-complementing group 4 (XRCC4) is a major repair gene for DNA double-strand breaks(DSB) in the non-homologous end-joining (NHEJ) pathway. Several potentially functional polymorphisms of theXRCC4 gene have been implicated in breast cancer risk, but individually published studies showed inconclusiveresults. The aim of this meta-analysis was to investigate the association between XRCC4 polymorphisms and therisk of breast cancer. Methods: The MEDLINE, EMBASE, Web of science and CBM databases were searchedfor all relevant articles published up to June 20, 2012. Potential associations were assessed with comparisons ofthe total mutation rate (TMR), complete mutation rate (CMR) and partial mutation rate (PMR) in cases andcontrols. Statistical analyses were performed using RevMan 5.1.6 and STATA 12.0 software. Results: Five studieswere included with a total of 5,165 breast cancer cases and 4,839 healthy controls. Meta-analysis results showedthat mutations of rs2075686 (C>T) and rs6869366 (G>T) in the XRCC4 gene were associated with increasedrisk of breast cancer, while rs2075685 (G>T) and rs10057194 (A>G) might decrease the risk of breast cancer.However, rs1805377 (A>G), rs1056503 (G>T), rs28360317 (ins>del) and rs3734091 (A>G) polymorphisms ofXRCC4 gene did not appear to have an influence on breast cancer susceptibility. Conclusion: Results from thecurrent meta-analysis suggest that the rs2075685 (G>T) and rs6869366 (G>T) polymorphisms of the XRCC4 genemight increase the risk of breast cancer, whereas rs2075685 (G>T) and rs10057194 (A>G) might be protectivefactors.     

Association between the DICER rs1057035 Polymorphism and Cancer Risk: Evidence from a Meta-analysis of 1,2675 Individuals

Background: DICER, one of the microRNA (miRNA) biogenesis proteins, is involved in the maturation ofmiRNAs and is implicated in cancer development and progression. The results from previous epidemiologicalstudies on associations between DICER rs1057035 polymorphism and cancer risk were inconsistent. Thereforeweperformed this meta-analysis to summarize possible associations. Materials and Methods: We searched allrelevant articles on associations between DICER rs1057035 polymorphism and cancer risk from PubMed,EMBASE, Chinese Biomedical Literature and Chinese National Knowledge Infrastructure until August 2014.Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess any associations. Heterogeneitytests, sensitivity analyses and publication bias assessments were also performed in this meta-analysis. All analyseswere conducted using STATA software. Results: Seven case-control studies, including 4,875 cancer cases and 7,800controls were included in the meta-analysis. Overall, the results indicated that the C allele of DICER rs1057035polymorphism was significantly associated with decreased cancer risk in allelic comparison, heterozygote anddominant genetic models (C vs T: OR=0.88, 95%CI 0.81-0.95, p=0.002; TC vs TT: OR=0.85, 95%CI 0.77-0.93,p=0.001; CC/TC vs TT: OR=0.86, 95%CI 0.78-0.94, p=0.001). In the subgroup analysis by ethnicity, a significantlydecreased cancer risk was found in Asian but not Caucasian populations. Conclusions: The present meta-analysissuggests that the C allele of the DICER rs1057035 polymorphism probably decreases cancer risk. However, thisassociation may be Asian-specific and the results should be treated with caution. Further well-designed studiesbased on larger sample sizes and group of populations are needed to validate these findings.     

Lack of any Association between the Hogg1 Ser326Cys Polymorphism and Breast Cancer Risk: a Systematic Review And Meta-Analysis Of 18 Studies

Background: The human 8-oxoguanine DNA glycosylase (hOGG1) gene may be linked with cancer susceptibility. The aim of this study was to quantitatively summarize any association between the hOGG1 Ser326Cys polymorphism and breast cancer (BC) risk. Materials and Methods: A comprehensive search of the PubMed, Embase, and ISI web of knowledge databases for papers published before 1 October 2016 was conducted. Summary odds ratios (ORs) with corresponding 95 % confidence intervals (95 %CIs) were estimated, with fixed-effects or random-effects models when appropriate, to assess any association. Results: A total of 9,434 cases and 10,497 controls from 18 studies were included in this meta-analysis. When the eligible studies were pooled, there was no evidence found for a significant association between the hOGG1 Ser326Cys polymorphism and BC in in all genetic contrast models G vs. C (OR=1.19, 95% CI 0.92– 1.53), CG vs. CC (OR = 0.97, 95% CI 0.91-1.04, p = 0.46), GG vs. CC (OR = 1.11, 95% CI 0.91-1.35, p = 0.30), GG + CG vs. CC (OR = 0.98, 95% CI 0.92-1.05, p = 0.67), and GG vs. CG + CC (OR = 1.22, 95% CI 0.98-1.52, p = 0.07). According to subgroup analysis, we also did not find a significant association between the hOGG1 Ser326Cys polymorphism and BC risk in Asians and Caucasians considered separately. Conclusions: The current meta-analysis suggests that the hOGG1 Ser326Cys polymorphism is not significantly associated with BC risk.     

Association of IL-12B rs3212227 and IL-6 rs1800795 Polymorphisms with Susceptibility to Cervical Cancer: A Systematic Review and Meta-Analysis

Background: Primary studies have shown that the IL-12B rs3212227 and IL-6 rs1800795 polymorphisms are associated with an increased risk of cervical cancer. However, conflicting results warrant a meta-analysis to obtain more precise estimates. Methods: A comprehensive literate search on PubMed, Web of Science, Scopus, CNKI, and SciELO was performed to collect all eligible studies up to November 10, 2019. The pooled odds ratios (OR) and 95% confidence intervals (CI) were used to calculate the risk. This meta-analysis was carried out by utilizing CMA software. Results: A total of eleven case-control studies including four studies on IL-12B rs3212227 and seven studies on IL-6 rs1800795 were selected. Pooled ORs revealed that the IL-6 rs1800795 polymorphism was significantly associated with an increased risk of cervical cancer (C vs. G: OR = 1.294, 95% CI 1.071-1.564, p= 0.007; CC vs. GG: OR = 1.633, 95% CI 1.059-2.520, p= 0.027; CC+CG vs. GG: OR = 1.312, 95% CI 1.048-1.643, p= 0.018; and CC vs. CG+GG: OR = 1.592, 95% CI 1.268-1.999, p≤0.001), but not IL-12B rs3212227 polymorphism. Stratified analysis by ethnicity revealed that both IL-12B rs3212227 and IL-6 rs1800795 polymorphisms were associated with risk of cervical cancer in Asian women. Conclusions: Our pooled data revealed that the IL-12B rs3212227 and IL-6 rs1800795 polymorphisms may be used to identify individuals at high risk of cervical cancer in Asian women.     

Lack of Association Between LIG4 Gene Polymorphisms and the Risk of Breast Cancer: A HuGE Review and Meta-analysis

Objective: Non-homologous end joining (NHEJ) is one of the pathways of repair of DNA double-strandbreaks. A number of genes involved in NHEJ have been implicated as breast cancer susceptibility genes such asLIG4. However, some studies have generated conflicting results. The aim of this Human Genome Epidemiology(HuGE) review and meta-analysis was to investigate association between LIG4 gene polymorphisms in the NHEJpathway and breast cancer risk. Methods: Studies focusing on the relationship between LIG4 gene polymorphismsand susceptibility to breast cancer were selected from the Pubmed, Cochrane library, Embase, Web of Science,Springerlink, CNKI and CBM databases. Data were extracted by two independent reviewers and the meta-analysiswas performed with Review Manager Version 5.1.6 and STATA Version 12.0 software, calculating odds ratios(ORs) with 95% confidence intervals (95%CIs). Results: According to the inclusion criteria, we final includedseven studies with a total of 10,321 breast cancer cases and 10,160 healthy controls in the meta-analysis. Theresults showed no association between LIG4 gene polymorphisms (rs1805386 T>C, rs1805389 C>T, rs1805388C>T and rs2232641 A>G) and breast cancer risk, suggesting that the mutant situation of these SNPs neitherincreased nor decreased the risk for breast cancer. In the subgroup analysis by Hardy-Weinberg equilibrium(HWE) and ethnicity, we also found no associations between the variants of LIG4 gene and breast cancer riskamong HWE, non-HWE, Caucasians, Asians and Africans. Conclusion: This meta-analysis suggests that thereis a lack of any association between LIG4 gene polymorphisms and the risk of breast cancer.     

Lack of Association between Hsa-Mir-499 rs3746444 Polymorphism and Cancer Risk: Meta-analysis Findings

Epidemiologic findings concerning the association between the hsa-mir-499 rs3746444 A>G polymorphismand cancer risk have yielded mixed results. We aimed to investigate the association by performing a meta-analysisof all available studies. We searched PubMed and EMBASE for studies published up to November 2014, usingodds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of any association. The Benjamini-Hochberg (BH) method was used to correct the p values for multiple comparisons. We included 39 studies,including 14,136 cases and 16,937 controls. The results of overall meta-analysis suggested a borderline associationbetween hsa-mir-499 rs3746444 polymorphism and cancer susceptibility (AG+GG vs. AA: OR=1.15, 95% CI=1.04-1.26, corrected p value=0.04). After removing studies not conforming to Hardy–Weinberg equilibrium(HWE), however, this association disappeared (AG+GG vs AA: OR=1.18, 95% CI=1.03-1.34, corrected pvalue=0.21). When stratified analysis by ethnicity, cancer type or HWE in controls, although some associationsbetween hsa-mir-499 rs3746444 polymorphism and cancer susceptibility were detected, these associations nolonger existed after adjustment using BH method. In conclusion, our meta-analysis suggests that hsa-mir-499rs3746444 A>G polymorphism is not associated with risk of cancer based on current evidence.